Search
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedIt present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. … A total of 10, 000 injections were administered to 2,028 patients undergoing angiocardiographic procedures over a three-year period.
Brincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021. … [L34470] As smallpox has been eradicated, the efficacy of Tembexa was assessed in animals infected with viruses closely related to variola.
Ambenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnAmbenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
Pranlukast
go.drugbank.com/drugs/DB01411InvestigationalIt antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Categories: Agents to Treat Airway DiseaseTalactoferrin alfa
go.drugbank.com/drugs/DB05426InvestigationalIt increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation. … Lactoferrin, a protein found in breast milk is developed by Agennix.
Mesoridazine
go.drugbank.com/drugs/DB00933ApprovedWithdrawnA phenothiazine antipsychotic with effects similar to chlorpromazine.
Atovaquone
go.drugbank.com/drugs/DB01117ApprovedInvestigationalAtovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalIt was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Desmoteplase
go.drugbank.com/drugs/DB04925InvestigationalIt activates plasminogen to the serine protease, plasmin. Plasmin acts by breaking down fibrin blood clots. … When a vampire bat bites its victim, it secretes an enzyme that prevents the blood from clotting.